Lantern Pharma (NASDAQ: LTRN), an AI-driven precision oncology company, announced the launch of ZetaOmics, the computational biology module of its multi-agentic AI co-scientist platform, withZeta.ai. The platform introduces an autonomous “Computational Biologist” agent capable of performing end-to-end bioinformatics and multi-omic analysis across various cancer types. Initially available through an early-access program for select academic, industry, and company collaborators, ZetaOmics is designed to automate complex research workflows while embedding domain-specific intelligence intended to improve analytical rigor and reproducibility.
According to the company, ZetaOmics combines 14 specialized tools that can autonomously design, execute, and validate biological analyses, detect potential flaws in experimental design, and generate publication-quality results with a complete audit trail. This capability is expected to significantly reduce the time and effort required for computational biology tasks, enabling researchers to focus on hypothesis generation and validation. By automating routine yet complex analyses, the platform aims to enhance the reproducibility of scientific findings, a persistent challenge in biomedical research.
The launch of ZetaOmics expands withZeta.ai’s commercial opportunity beyond rare cancers, targeting academic medical centers, biotechnology and pharmaceutical companies, cancer centers, and contract research organizations through subscription-based offerings and strategic collaborations. This move represents a strategic pivot for Lantern Pharma, as it seeks to monetize its AI platform independently of its drug development pipeline. The company had previously focused on leveraging its RADR platform to identify and develop therapies for rare and hard-to-treat cancers, but with ZetaOmics, it now offers a research tool that can serve a broader market.
Lantern Pharma’s clinical pipeline includes LP-184, a candidate for acylfulvene-based therapy; LP-284, a TC-NER targeting compound for hematologic and solid tumors; and LP-300, a cisplatin/ethacraplatin analog being evaluated in the HARMONIC Phase 2 trial for never-smoker patients with relapsed advanced lung adenocarcinoma. LP-184 is also being developed for pediatric CNS cancers through Starlight Therapeutics, the company’s wholly owned CNS-focused subsidiary. Despite these promising candidates, the commercial launch of ZetaOmics signals a diversification strategy that could provide additional revenue streams independent of clinical trial outcomes.
The platform’s ability to autonomously detect flaws in experimental design and generate audit trails addresses a critical need for transparency and reproducibility in computational biology. By embedding domain-specific intelligence, ZetaOmics aims to reduce the risk of erroneous conclusions that can arise from inadequately designed analyses. This feature is particularly valuable for academic and industry researchers who increasingly rely on large-scale omics data to inform drug discovery and biomarker identification.
Lantern Pharma operates an AI Center of Excellence in Bengaluru, India, and is headquartered in Dallas, Texas. The company’s expansion into computational biology services reflects a broader trend where AI-driven drug developers are creating standalone platforms to generate revenue while advancing their core therapeutic missions. As the platform becomes more widely adopted, it could position Lantern as a key player in the computational biology market, which is projected to grow substantially in the coming years.
For more information, visit the full press release at https://ibn.fm/9sIIl.
